Notably, a myokine, irisin, has been reported to ameliorate experimental colitis and reduce the colonic TNF-α concentration (34), suggesting that the skeletal muscle condition is a new treatment target for CD, as well as a predictive marker of the effect of anti-TNF therapy. This evidence concerns the gene FNDC5 and Cowden disease.